No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection-Reference-Cited by-同舟云学术

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

Published:2018-10 Issue:10 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cathcart Andrea L.¹^ORCID,Chan Henry Lik-Yuen²,Bhardwaj Neeru¹,Liu Yang¹,Marcellin Patrick³,Pan Calvin Q.⁴^ORCID,Shalimar ⁵,Buti Maria⁶,Cox Stephanie¹,Parhy Bandita¹,Zhou Eric¹,Martin Ross¹,Chang Silvia¹,Lin Lanjia¹,Flaherty John F.¹,Kitrinos Kathryn M.¹,Gaggar Anuj¹,Izumi Namiki⁷,Lim Young-Suk⁸

Affiliation:

1. Gilead Sciences, Foster City, California, USA

2. Department of Medicine and Therapeutics, Institute of Digestive Disease and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong

3. Service d'Hépatologie, Hôpital Beaujon, Clichy, France

4. Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Medical Center, NYU School of Medicine, New York, New York, USA

5. Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India

6. Hospital Universitari Vall d'Hebron, Barcelona, Spain

7. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan

8. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Abstract

Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF). However, limited data are available for its resistance profiles.

Funder

Gilead Sciences

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01064-18

Reference51 articles.

1. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

2. Long-term safety of lamivudine treatment in patients with chronic hepatitis B

3. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase